Clearmind Medicine completes initiation at TASMC for Phase I/IIa trial

Clearmind Medicine (CMND) announced the completion of site initiation at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder. This milestone advances Clearmind’s mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for 2.6 million deaths annually. The Phase I/IIa trial, already underway at sites, including Yale School of Medicine and Johns Hopkins University in the United States and TASMC and Hadassah-University Medical Center in Israel, is a multinational, multi-center study assessing the safety, tolerability, and pharmacokinetic profile of CMND-100. It also explores early efficacy signals, such as reduced alcohol cravings and consumption, in patients with AUD. The inclusion of TASMC as a clinical site, where the trial is led by Prof. David Zeltser, Director of the Emergency Medicine Department at TASMC, strengthens Clearmind’s clinical network and accelerates patient enrollment in this groundbreaking trial.